Philips published a U.S. pivotal study showing that only 1% Type D–F flow-limiting dissections were reported post-AngioSculpt.
Published
Signal category
Research & Knowledge
Quote
“A U.S. pivotal study reported only 1% Type D–F flow‑limiting dissections post‑AngioSculpt”
— Kelly Allbright, BA, RT(R)|Philips team
Company
Philips
Better care for more people. 💙
- Industry
- Hospitals and Health Care
- Location
- Amsterdam, NL
- Company size
- 74,012 employees
Over the past decade we have transformed into a focused leader in health technology. At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. Visit our website: http://www.philips.com/ Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html